Prolonging the effects of botulinum therapy: A milestone in neuromuscular disease management

Botulinum toxin-A (BTX), also known as Botox, is used to treat a range of neuromuscular disorders, including muscle spasms, dystonia, eye twitching, overactive bladder, and spasticity associated with cerebral palsy or stroke. Notably, BTX has gained popularity in cosmetology owing to its effectiveness in minimizing facial wrinkles. BTX works by inducing paralysis at neuromuscular junctions (NMJs)—the connections between a neuron (brain cell) and a muscle fiber.

Study sheds light on sporadic early-onset Alzheimer’s disease, potential target for novel treatment

Alzheimer’s disease (AD), the most prevalent neurodegenerative disease globally, poses a significant threat to human health. Most AD patients are diagnosed after the age of 65, categorized as late-onset AD (LOAD). However, about 5%–10% of AD patients show symptoms before the age of 65, exhibiting the same pathological characteristics as AD, classified as early-onset AD (EOAD).

Study identifies the top three genes responsible for traumatic brain injury complications

The severity of traumatic brain injury (TBI) has been underscored in the last decade as doctors seek to understand its role in neurological diseases like chronic traumatic encephalopathy (CTE), a progressive and fatal brain disorder caused by repeated head injury that gained notoriety for its markedness among NFL pros including Mike Webster and Aaron Hernandez.